Sanity Group, a Berlin, Germany-based healthcare firm centered on cannabinoids and the endocannabinoid system, raised $37.6M in SeriesB funding.
The spherical, which brings brings whole funds raised up to now to over $100m, was led by BAT Group with participation from Will.I.Am, Alyssa Milano, Scooter Braun, Redalpine, Casa Verde Capital, HV Capital, Calyx, TQ Ventures, Atlantic Meals Labs, Cherry Ventures, Bitburger Ventures, SevenVentures, GMPVC, Navy Capital and SOJE Capital.
The corporate intends to make use of the funds to speed up its development, allow European enlargement and strengthen analysis and growth actions.
Led by CEO Finn Age Hänsel, Sanity Group goals to enhance individuals’s high quality of life by way of the usage of cannabinoids and the endocannabinoid system. Along with prescription drugs, the corporate’s focus can be on wellbeing and beauty merchandise that make the most of cannabinoids. Based in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, Sanity Group consists of Vayamed and AVAAY Medical (medicinal hashish), Endosane Prescription drugs (completed prescription drugs), Belfry Medical (medical merchandise and digital purposes), VAAY (wellbeing) and This Place (pure cosmetics). Sanity Group additionally operates a manufacturing and processing facility for hashish extracts close to Frankfurt am Principal.
The corporate has round 120 workers within the medical, client well being and science sectors.